

COM-2023-016

28
MARCH
2023

PLEASE REVIEW Drug Information

PharmPix Clinical Department

Drug Information:

Remember that medical literature is dynamic and is continuously changing as new scientific knowledge is developed. We exhort the frequent revision of treatment guidelines to assure that your recommendations are consistent with the most updated information.

It is our priority to offer high-quality services and support practices for health promotion and diseases prevention. If you have any questions or wish to have more information regarding this document, you can call us directly or view PharmPix communications online.

QUESTIONS

Call us at 787-522-5252, ext. 220

Access our recent communications at our providers' portal:
<https://www.pharmpix.com/providers/>



PharmPix is committed to the health and wellness of our members.

The clinical team wants to communicate the latest up-to-date drug information.

Insulin Price Reduction

Three drug manufacturers have announced insulin price reductions. Here's a brief update on the reductions:

Eli Lilly and Co.

- List price of unbranded insulin, insulin lispro injection 100units/mL, will be cut to \$25 a vial, effective May 1, 2023.
- List price of Humalog™ and Humulin™ will be cut by 70%, effective in fourth quarter 2023.
- List price at launch of Rezvoglar™, an interchangeable biosimilar to Lantus™, will be \$92 per five pack of KwikPens, a 78% discount to Lantus™, effective April 1, 2023.
- Expansion of its Insulin Value Program that caps patient out-of-pocket costs at \$35 or less per month.

Novo Nordisk

- List price of Novolog™ (FlexPen and vial) and Novolog™ Mix (FlexPen and vial) will be reduced by 75%.
- List price of unbranded Novolog™, insulin aspart (FlexPen and vial), and unbranded Novolog™ Mix FlexPen, insulin aspart protamine/insulin aspart 70/30, will be reduced by 50%. The vial for insulin aspart protamine/insulin aspart 70/30 will be reduced by 52%. This reduction in the list price is to match the lowered price of each respective branded insulin.
- List price for Levemir™ and Novolin™ (FlexPen and vial) will be reduced by 65%.
- These insulin price reductions will be effective starting on January 1, 2024.

Sanofi

- List price of Lantus™ (SoloStar and vial) will be cut by 78%.
- List price of Apidra™ (SoloStar and vial) will be cut by 70%.
- Cap on out-of-pocket costs for Lantus™ at \$35 for all patients with commercial insurance.
- These changes will be effective on January 1, 2024.

Please refer to the Press Release of each drug manufacturer for more details:

- [Eli Lilly and Co. Press Release: Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at \\$35 Per Month](#)
- [Novo Nordisk Press Release: Novo Nordisk to lower U.S. prices of several pre-filled insulin pens and vials up to 75% for people living with diabetes in January 2024](#)
- [Sanofi Press Release: Sanofi cuts U.S. list price of Lantus™, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at \\$35 for all patients with commercial insurance](#)

If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252-ext. 220. Our pharmacists will help you. In addition, know that you can access our recent communications at our providers' portal: <https://www.pharmpix.com/prviders/>.

PharmPix Drug Information Communication Number COM-2023-016 March 2023



REFERENCES:

1. Lilly cuts insulin prices by 70% and caps patient insulin out-of-pocket costs at \$35 per month. Eli Lilly and Company. (2023, March 1). <https://investor.lilly.com/news-releases/news-release-details/lilly-cuts-insulin-prices-70-and-caps-patient-insulin-out-pocket>
2. Novo Nordisk to lower U.S. prices of several pre-filled insulin pens and vials up to 75% for people living with diabetes in January 2024. (2023, March 14). <https://www.novonordisk.com/news-and-media/latest-news/lowering-us-list-prices-of-several-products-.html#:~:text=PLAINSBORO%2C%20NJ%2C%20March%2014%2C.1%20and%20type%20%20diabetes>.
3. Sanofi cuts U.S. list price of Lantus, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at \$35 for all patients with commercial insurance. (2023, March 16). <https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-16-20-06-43-2629188>

2 Street 1, Suite 500
Guaynabo, PR 00968

Tel. 787.522.5252
Fax 866.912.2830

www.pharmpix.com
FRM-CL-000130-001



CLINICAL PEARLS
BY PHARMPIX